RhumbLine Advisers
ANRO icon

RhumbLine Advisers’s Alto Neuroscience ANRO Stock Holding History

RhumbLine Advisers’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Buy
+31,636
New +$732K ﹤0.01% 2433
2025
Q2 		– Sell
-27,127
Closed -$58.6K – 4280
2025
Q1 		$58.6K Buy
27,127
+1,571
+6% +$5.62K ﹤0.01% 3536
2024
Q4 		$108K Buy
25,556
+5,008
+24% +$31.3K ﹤0.01% 3458
2024
Q3 		$235K Buy
20,548
+10,009
+95% +$122K ﹤0.01% 3155
2024
Q2 		$113K Buy
+10,539
New +$137K ﹤0.01% 3487

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RhumbLine Advisers's ANRO Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Alto Neuroscience (ANRO) in Q2 2026: 31,636 shares worth $835K. The stake represents ﹤0.01% of the portfolio and ranks #2433 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ANRO as recently as Q1 2025.

RhumbLine Advisers first reported a position in ANRO in Q2 2024 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • RhumbLine Advisers held 31,636 shares of Alto Neuroscience worth $835K as of Q2 2026.
  • Alto Neuroscience was a new RhumbLine Advisers position in Q2 2026.
  • Alto Neuroscience made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2433 holding.
  • RhumbLine Advisers first reported a position in Alto Neuroscience in Q2 2024 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.